Pneumocystis jirovecii diagnosed by next-generation sequencing of bronchoscopic alveolar lavage fluid: A case report and review of literature

Qing-Wei Cheng,Hong-Li Shen,Zhi-Hui Dong,Qian-Qian Zhang,Ya-Fen Wang,Jin Yan,Yu-Sheng Wang,Ning-Gang Zhang
DOI: https://doi.org/10.12998/wjcc.v11.i4.866
2023-02-06
World Journal of Clinical Cases
Abstract:BACKGROUND: The advent of molecular targeted agents and immune checkpoint inhibitors has greatly improved the treatment of advanced renal cell carcinoma (RCC), thus significantly improving patient survival. The incidence of rare drug-related adverse events has gained increased attention.CASE SUMMARY: We report a patient with advanced RCC treated with multiple lines of molecular targeted agents and immune checkpoint inhibitors, who developed a pulmonary infection after treatment with everolimus in combination with lenvatinib. Determining the pathogenic organism was difficult, but it was eventually identified as <i>Pneumocystis jirovecii</i> by next-generation sequencing (NGS) of bronchoscopic alveolar lavage fluid (BALF) and successfully treated with trimethoprim-sulfamethoxazole.CONCLUSION: Rare pulmonary infections caused by molecular targeted agents are not uncommon in clinical practice, but their diagnosis is difficult. Evaluating BALF with NGS is a good method for rapid diagnosis of such infections.
medicine, general & internal
What problem does this paper attempt to address?